anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: New-Onset Refractory Status Epilepticus (NORSE) is a rare and severe form of refractory status epilepticus without an apparent underlying cause at presentation or prior history of epilepsy. We aimed to describe the clinical features, etiology, treatment, and outcomes of NORSE in adults in a quaternary-level hospital in Saudi Arabia.
METHODOLOGY: In this retrospective cohort study, inclusion criteria involved patients over 14 years old who met the 2018 consensus definition for NORSE. Patients were identified using a combination of medical record admission labels 'status epilepticus' and 'encephalitis', and continuous EEG reports documenting status epilepticus. Demographic, clinical, and radiological data were collected and then analyzed for factors correlated with specific etiologies, better functional outcomes, and future diagnosis of epilepsy.
RESULTS: We found 24 patients presenting with NORSE between 2010 and 2021. Fever/infectious symptoms were the most common prodrome. Elevated inflammatory serum and cerebrospinal fluid markers in most patients. Brain MRI revealed T2/FLAIR hyperintensity patterns, predominantly affecting limbic and perisylvian structures. The etiology of NORSE varied, with immune-related causes being the most common. Long-term outcomes were poor, with a high mortality rate and most survivors developing drug-resistant epilepsy.
CONCLUSION: This study provides valuable insights into NORSE's clinical characteristics, highlighting the heterogeneity of this condition. The poor outcome is likely related to the progressive nature of the underlying disease, where refractory seizures are a clinical symptom. Thus, we propose to focus future research on the etiology rather than the NORSE acronym.
Liothyronine/levothyroxine (LT3/LT4) combination therapy. LT4/LT3 group will have 25 mcg of LT4 substituted with 5 mcg LT3 twice daily, to mimic the average daily T3 production form the thyroid The VCU Investigational Pharmacy will over-encapsulate LT4 plus 5 mcg LT3 in "AM" and "PM" color coded capsules. Patients will be instructed to take the AM drug first thing in the morning with water only, and to wait at least 30 minutes before taking other medications coffee or breakfast. The PM dose will be taken at least 30 minutes before dinner. Dose adjustments will be performed at the 6-week and 3-month follow up visits by an unblinded endocrinologist (Dr. Yavuz) aiming to achieve and maintain a target TSH within the normal range and within ± 0.5 mcIU/ml from the baseline (pre-surgery) TSH, Doses will be rounded to the nearest available formulation. No changes will be made in LT3.
In this group, 20 participants will be included. Rhythmic Stabilization with traditional physical therapy will be given for 3 sessions of 45 minutes a week, over a period of 10 weeks.
System for controlled release of morphine and other water- soluble drugs by complex formation with polymeric substances. Method for obtaining a system for controlled release of drugs with high water solubility by complex formation with polymeric substances, which consists in causing an acrylic resin, e.g. Eudragit L 30D, to react chemically with the salt of the drug in question, e.g. morphine. A determined volume of an aqueous suspension of Eudragit L 6D is first partially neutralized, and to this the aqueous solution of the salt of the drug with which the complex is to be formed is subsequently added, producing a reaction between the drug and the resin, and a precipitate is obtained which, when dried in a drying chamber, gives rise to the drug-Eudragit complex. It is applicable in the pharmaceutical industry for the manufacture of solid formulations for oral administration which allow therapeutic plasma concentrations to be quickly attained and subsequently maintained for a prolonged period until the active principle is completely released, thus optimizing the pharmacotherapy.
This is a Methodology and Computer System to "Optimize Human Mind by Recording a Brief Story of Time from the perspective of Observer Intelligent Agents". As defined in Artificial Intelligence, every Human is an Intelligent Agent.  Intelligent Agents receive percepts from their environment and perform actions in Time. An Observer Intelligent Agent is a Human who is watching Time (as the container of life) and therefore is outside of the Story. This perspective allows Agents to become more aware of the content of their Minds (feelings, thoughts, life situations, knowledge) and detach from it. The Brief Story of Time spans from January 01 0001 to January 01 2500 [25 Volumes (centuries), 250 Chapters (decades), 2,500 Sections (years), 912,500 Moments (days)] and the perspective of a human is 2.5% of the entire story based on age. Using Aggregated Data, Statistical Reports, and Tags, Individual and Collective Intelligence Factories can be created.
BACKGROUND: Surgical extraction of impacted third molars (ITM) often leads to postoperative discomfort including pain, swelling, and limited function. Steroids like dexamethasone (DXN) are commonly used in oral surgery to manage pain and inflammation. Various administration routes for DXN exist, including intravenous (IV), perineural (PN), and oral applications, each with its advantages. Previous studies have shown that adding DXN to local anesthetics can prolong anesthesia duration and reduce postoperative sequelae. However, comparative studies on IV and PN applications with inferior alveolar nerve block (IANB) of DXN in ITM surgeries are limited.
METHODS: This controlled, randomized observational study involved patients undergoing Class II position B ITM extraction. Patients were divided into three groups. IANB (1.8 ml of articaine hydrochloride + 1 ml of saline) was performed 1 h after IV-DXN (4 mg/ml DXN) was administered to the IV group. DXN along with IANB (1.8 ml of articaine hydrochloride + 1 ml of 4 mg/ml DXN) was applied to the PN group. Only IANB (1.8 ml of articaine hydrochloride + 1 ml of saline) was applied to the control group. Anesthesia duration was assessed as primary outcomes. Anesthesia duration was evaluated using a vitalometer from the molars. Secondary outcomes included postoperative pain and edema measured on the 1st, 3rd, and 7th days after surgery. Pain was evaluated postoperatively by using a visual analog scale. A p-value < 0.05 was considered statistically significant.
RESULTS: The study included 45 patients with similar demographic characteristics across groups. IV application significantly prolonged anesthesia duration compared to the control group. (p = 0.049) Both IV and PN administration of DXN reduced postoperative edema at 3rd (p = 0.048) and 7th day (p = 0.01). Post-procedure pain reduction was significant in the IV group (p = 0.011). On the other hand, it was observed that the pain did not decrease in the PN group at 3rd and 7th days compared to the control and IV groups.
CONCLUSIONS: PN and IV DXN administration prolonged anesthesia duration and reduced postoperative edema in ITM surgeries. However, PN DXN administration was associated with increased postoperative pain compared to IV DXN and control groups. Further studies comparing different doses and administration routes of DXN are needed to determine optimal strategies for managing postoperative discomfort in ITM surgeries.
TRIAL REGISTRATION: This study was conducted at Ahmet Keleşoğlu Faculty of Dentistry with the permission of Karamanoğlu Mehmetbey University Faculty of Medicine Ethics Committee (#04-2022/101). Trial registration is also available at clinicaltrail.gov. (NCT06318013, 26/05/2024).
Various topical interventions have been described to minimize botulinum neurotoxin-A (BoNT)-induced pain. The purpose of this study is to conduct a systematic review of relevant randomized controlled trials (RCTs) to compare the efficacy of pain relief methods during BoNT injection. PubMed, Scopus, and Web of Science were searched using "Botox," "Botulinum," or "BTX." We identified RCTs in which BoNT were injected to eliminate wrinkles. The pain score was the study outcome, and pain reduction method was compared with routine one. The meta-analysis was reported using the PRISMA checklist. The Higgins I(I2) statistical model assessed results heterogeneity. Two thousand one hundred and twenty-three articles were identified, thirteen articles eligible. Two hundred and sixty-two healthy volunteers were performed on these RCTs. Meta-analysis evaluated different methods to ease BoNT injection pain, and these methods significantly improved outcomes by 0.23% (95%CI, 0.11-0.46, p = .000). Subgroup analysis based on injection area showed no significant heterogeneity, but heterogeneity decreased when subgroup analysis based on other methods was done (Cochran's Q test = 115.52, p = .0001, I2 = 87.9%). This meta-analysis confirms the effectiveness of pain relief methods during BoNT injection. Evaluation of different methods showed their effectiveness, but finding the best method requires comparative studies, although the role of pH and EMLA has been proven.
Participants will receive 1200mg Adebrelimab i.v. once every 3 weeks and 20 mg Famitinib orally before or after the meal every day for 3 weeks until PD and/or endurable toxicity appears.
PURPOSE: An anticancer agent composition containing an organic solvent extract of Eurya emarginata(Thunb.) Makino having an inhibition effect on the proliferation of tumor cells is provided. The composition is low in toxicity and inhibits the growth of cancer cells by inducing apoptosis thereof. CONSTITUTION: Leaves of Eurya emarginata(Thunb.) Makino are ground, soaked in 2 to 20 times of a solvent, agitated at room temperature for 20 to 30hr, filtered and concentrated under reduced pressure. The anticancer agent composition contains the Eurya emarginata extract and a pharmaceutically acceptable salt selected from a diluent, a flavoring, solubilizing agent, a lubricating agent, a binding agent and a disintegrating agent. The solvent is selected from methanol, ethanol, butanol, propanol, hexane, ethyl acetate, acetone, chloroform, methylene chloride and a mixture thereof. The effective daily dose of the extract is 10 to 60mg/kg of body weight.
PURPOSE:To provide a safe and excellent antidementia agent containing a 2-pyrrolidone-5-carboxylic acid derivative as an active component, exhibiting anti-amnestic effect by oral administration and having low toxicity. CONSTITUTION:The objective agent contains a compound of formula I (A is phenyl or pyridyl which may have halogen as a nucleus substituent; n is 1-4; Y is -O- or -NH-) as an active component. The compound is mixed with various drug additives such as excipient, disintegrant, condensation agent or lubricant and used in various forms such as tablet or powder. The daily rate of administration for adult is 50-1,000mg in the case of oral administration and 1-500mg for parenteral administration. The compound of formula I can be synthesized e.g. by reacting the compound of formula II with the compound of formula III preferably in the presence of a condensation agent (e.g. N,N'- dicyclohexylcarbodiimide).
BACKGROUND: Thoracic disk herniations (TDHs) are relatively rare compared with their cervical and lumbar counterparts. Posterior approaches allow for a simpler and less invasive surgery than anterior and lateral approaches. A pedicle-sparing transfacet approach was initially described in 1995, and modified in 2010. A few clinical series have reported the outcome of this procedure in patients with TDH. This study aimed to evaluate the outcomes and complications of pedicle-sparing transfacet diskectomy with interbody fusion and segmental instrumentation in patients with TDH.
METHODS: Twenty-one consecutive patients with symptomatic TDH referred to our tertiary care center were included in this retrospective study. All patients underwent a pedicle-sparing transfacet diskectomy with polyetheretherketone (PEEK) cage interbody fusion and short segmental instrumentation. Distribution of TDH, operative duration, blood loss, Visual Analog Scale (VAS) pain scores, Nurick grades, modified Japanese Orthopaedic Association (mJOA) scores, and fusion rate were assessed.
RESULTS: All patients had single-level herniations. The most common location was T12-L1 (38.1%), followed by T11-T12 (33.3%). All patients were successfully operated on with no cerebrospinal fluid (CSF) leaks or wrong-level surgery. The VAS scores significantly diminished from 4.9 (preoperatively) to 2 (18 months after surgery). The average mJOA score increased from 4.6 to 8.5, and the average Nurick grade decreased from 3.1 to 1.6. All patients reported significant improvement in quality of life relative to their preoperative status.
CONCLUSION: A modified pedicle-sparing transfacet diskectomy combined with PEEK cage interbody fusion and segmental instrumentation offers a safe and less invasive approach for the treatment of TDHs.
Individuals previously diagnosed with obsessive compulsive disorder (OCD). Participants must be 18 years of age or older.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and can be used for treating chronic toxic alcohol- and tobacco-related optic neuropathy. For this purpose, the method involves the first stage of staying in hospital for 10 days whereat the patient is prescribed with intravenous introduction of nootropyl and cerebrolysin 5-10 ml, intramuscular injections of glutoxim 2.0 ml and mexidol 1.0-2.0 ml, parabulbar injections of dexamethasone 0.5 ml, and oral administration of heptane 1 tablet 3 times a day. It is added with 10 daily sessions of percutaneous electrical stimulation of optic nerves starting with the first day of treatment. The second stage is outpatient, starts from the 11th day and takes another 10 days to prescribe intramuscular injections of corthexin 10 mg, proserin 0.5-1.0 ml, milgamma 2.0 ml, parabulbar injections of emoxipin 0.5 ml, and 10 sessions of magnetic stimulation of the optic nerve. The one-month outpatient third stage starts from the 21th day and involves oral administration of pantogam 1 tablet 3 times a day and phenotropyl 1 tablet 1 time a day. ^ EFFECT: method provides improved visual functions in the case patients. ^ 2 ex, 3 tbl
Urothelial carcinoma has several histological types, extensive genetic diversity and a wide array of risk factors related to disease development. Moreover, the treatment effectiveness may be widely impacted by factors such as age, previous comorbidities, socio-economic factors, late diagnosis and access to treatment. In the last decade, the treatment profile has evolved worldwide with the incorporation of new technologies, however, there is no data on Brazilian reality in this period. In a continent-sized country and such heterogeneous health services as Brazil, preparing such knowledge becomes more important and challenging. This paper proposed to describe early urothelial carcinoma presentation pattern and treatment in Brazilian population (high-risk non-muscle-invasive and localized muscle-invasive) in several sites spread throughout the national territory. Thus, data will be generated to provide a more appropriate understanding of the current landscape and, consequently, the better design of public policies to face this disease.
This is a prospective imaging study evaluating the utility of baseline metabolic MR imaging as a predictive response biomarker to androgen signaling inhibition in patients with castration-resistant prostate cancer. Patients with a target lesion that is amenable for metabolic MR imaging will be eligible for study participation. Patients will undergo baseline metabolic MR imaging with Hyperpolarized Pyruvate C-13 pyruvate followed by initiation of androgen signaling inhibition (either as standard of care or as part of clinical trial; including abiraterone and/or enzalutamide treatment). Patient will subsequently undergo repeat metabolic MR scan after 28 days (+/- 7 days) of therapy. For those without primarily refractory disease, a third metabolic MR scan will be completed at the time of radiographic disease progression by The Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria. MR- or CT-guided tumor biopsies are optional at baseline and at the time of disease progression.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to novel derivatives of arylethenosulfone-amide of the formula (I)   or its pharmaceutically acceptable salts that show high affinity to endothelin and can be used in medicine. In compound of the general formula (I) Ar means phenyl that can be substituted with 1-3 substituents taken among the group: halogen atom, lower alkyl possibly substituted with 1-3 substituents taken among halogen atom; lower alkoxyl, lower alkoxycarbonyl, carboxy-group, cyano-group; naphthyl, 5-6-membered heteroaryl taken among the group: thienyl, furyl, thiazolyl, pyridyl, pyrimidyl; X is oxygen, sulfur atom or group -NH-; Y is oxygen atom; R 1  is lower alkyl that can be substituted with halogen atoms, cyclo-alkyl, phenyl that can be substututed with 1-3 substituents taken among lower alkyl possibly substituted with 1-3 halogen atoms, lower alkoxyl, nitro-group, C 1 -C 3 -alkylenedioxy-group, 5-6-membered heterocycle taken among the group including pyridyl, pyrimidyl, thiazolyl, furyl, thienyl being each of that can be substituted with lower alkyl possibly substituted with 1-3 halogen atoms, lower alkoxy; R 2  is lower alkyl, lower alkenyl being each of that can be substituted with 1-3 groups taken among the group including hydroxy-group, lower alkoxy-group, halogen atom, cycloalkyl; R 3  is phenyl that can be substituted with 1-4 substituents taken among the group including lower alkyl, lower alkoxy-group, lower alkoxy-carbonyl; R 4  and R 5  can be similar or distinct and mean hydrogen atom, lower alkyl, or their pharmaceutically acceptable salt. Invention relates to also the pharmaceutical composition showing properties of endothelia antagonist and including derivatives of arylethenosulfoneamide or its pharmaceutically acceptable salt by p. 1 and pharmaceutically acceptable carrier. EFFECT: new compounds indicated above, valuable medicinal properties. 3 cl, 9 tbl, 95 ex
An herbal formulation for prevention and treatment of Diabetes and associated complications comprising extracts from selected Indian medicinal herbs  Emblica officinalis  Gaertn. of the Euphorbiaceae Family, Species of herbs of the Genus  Salacia  of the of the Celastraceae family, Species  Strychnos potatorum  L. f. of the Strychnaceae family, Species  Vetiveria zizanioides  (L.) Nash of the Poaceae family, Species  Curcuma longa  L. of the Zingiberaceae family, Species of herbs of the Genus  Aerva  of the Amaranthaceae family, Species of herbs of the Genus  Biophytum  of the Oxalidaceae family, Species of herbs of the Genus  Syzygium  of the Myrtaceae family, Species  Mangifera indica  L. of the Anacardiaceae family, Species of herbs of the Genus  Cyclea  and/or the Genus  Cissampelos  of the Menispermaceae family, Species of herbs of the Genus  Embelia  of the Myrsinaceae family, Species of herbs of the Genus  Cyperus  of the Cyperaceae family, Species  Terminalia chebula  (Gaertn.) Retz. of the Combretaceae family, Species  Centella asiatica  (L.) Urban of the Apiaceae family and/or the Species  Strychnos nux-vomica  L. of the Strychnaceae family and/or the Species  Butea frondosa  Koen. ex Roxb. of the Papilionaceae family and/or the Species  Acacia catechu  (L.f.) WiIId. of the Mimosaceae family, Species  Coscinium fenestratum  (Gaertn.) Colebr. of the Menispermaceae family and/or the Species of herbs of the Genus  Berberis  of the Berberidaceae family, and species of herbs of the Genus  Zizyphus  of the Rhamnaceae family. The invention has associate formulations for different diabetes related complications, which are individually useful in clinical requirements such as improving renal health and preventing renal diseases, preventing diabetic retinopathy and prevention and treatment for oxidative damage to heart and blood vessels. The invention is versatile and can be processed into extracts/concentrates and further pharmacologically modified to tablets or capsules or granules or syrups or herbal health drink or inhalable herbal medicinal preparations or ocular preparations or transdermal absorbable preparations such as ointments/gels or injectable medicine.
A pharmaceutical composition for use in a method of treating a metabolic, neurodegenerative, neurological, inflammatory or autoimmune disease, disorder or condition or cancer in a subject, wherein the composition comprises a 3-hydroxybutyric acid (3-HB) delivery means, 3-HB or a combination thereof and the method comprises delivering the 3-HB delivery means, the 3-HB or the combination thereof to the lower gastrointestinal (GI) tract. Preferably at least 90% of the 3-HB is the (R)-isomer ((R)-3-HB). The 3-HB delivery means may be a biological delivery system consisting of anaerobic bacteria that produce 3-HB. Preferably the anaerobic bacteria are genetically engineered wherein the anaerobic bacteria are butyrate producing bacteria comprising a non-native gene capable of expressing (R)-3-hydroxybutyryl-CoA dehydrogenase. Preferably the bacteria are from the clostridium genus, in particular clostridium butyricum. Preferably the composition is administered orally and is formulated for modified-release, preferably to the colon or terminal ileum. The composition may comprise a modified-release layer or coating surrounding a core comprising the 3-HB delivery means, the 3-HB or combination thereof.
An evaluating method of microvascular invasion in hepatocellular carcinoma and an evaluating system thereof are provided. The evaluating method of microvascular invasion in hepatocellular carcinoma includes steps as follows. A computed tomography image of a subject is provided, a region of interest labeling step is performed, an edge cutting step is performed, a predicting step is performed, and a determining and classifying step is performed. The computed tomography image includes a tumor area. The region of interest labeling step is to label a region of interest on the computed tomography image. The edge cutting step is to cut off the edge of the region of interest so as to obtain a cut region of interest. Each of a side length of the cut region of interest is 0.5 times to 1 times of each of a side length of the region of interest. Therefore, the goal of rapidly predicting and precisely determining of microvascular invasion according to computed tomography images from different sources can be achieved.
Anemia is sometimes seen in patients receiving NSAIDs, including fenoprofen calcium tablets. This may be due to fluid retention, occult or gross GI blood loss or an incompletely described effect upon erythropoiesis. Patients on long-term treatment with NSAIDs, including fenoprofen calcium tablets, should have their hemoglobin or hematocrit checked if they exhibit any signs or symptoms of anemia. NSAIDs inhibit platelet aggregation and have been shown to prolong bleeding time in some patients. Unlike aspirin, their effect on platelet function is quantitatively less, of shorter duration, and reversible. Patients receiving fenoprofen calcium tablets who may be adversely affected by alterations in platelet function, such as those with coagulation disorders or patients receiving anticoagulants, should be carefully monitored.